Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma

Abstract

In previously treated patients with <i>FGFR2</i> fusion or rearrangement-positive intrahepatic cholangiocarcinoma, the use of futibatinib, a covalent FGFR inhibitor, led to measurable clinical benefit. (Funded by Taiho Oncology and Taiho Pharmaceutical; FOENIX-CCA2 ClinicalTrials.gov number, NCT02052778.).